Immunocore Holdings(IMCR)
$28.88-1.06 (-3.54%)
IMCR
Immunocore Holdings financials statements
$28.88
At close:-1.06 (-3.54%)
Want to see IMCR full AI Analyst Report?
Immunocore Holdings (IMCR) Ratios
258 Followers
Immunocore Holdings Ratios
IMCR's free cash flow for Q3 2026 was £17.74M. For the 2026 fiscal year, IMCR's free cash flow was decreased by £-2.35M and operating cash flow was £20.09M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.04 | 4.38 | 3.80 | 4.70 | 4.29 |
| Quick Ratio | 4.01 | 4.36 | 3.77 | 4.69 | 4.29 |
| Cash Ratio | 1.90 | 2.15 | 3.18 | 3.99 | 3.89 |
| Solvency Ratio | -0.05 | -0.06 | -0.22 | -0.21 | -0.98 |
| Operating Cash Flow Ratio | -0.04 | 0.12 | 0.02 | -0.49 | -1.73 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | £ 310.51M | £ 281.07M | £ 300.66M | £ 286.12M | £ 178.83M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.41 | 0.43 | 0.14 | 0.15 | 0.21 |
| Debt-to-Equity Ratio | 1.15 | 1.20 | 0.23 | 0.24 | 0.37 |
| Debt-to-Capital Ratio | 0.53 | 0.55 | 0.19 | 0.19 | 0.27 |
| Long-Term Debt-to-Capital Ratio | 0.51 | 0.52 | 0.12 | 0.12 | 0.18 |
| Financial Leverage Ratio | 2.80 | 2.80 | 1.62 | 1.55 | 1.76 |
| Debt Service Coverage Ratio | -0.97 | -1.96 | -8.93 | -8.87 | -29.94 |
| Interest Coverage Ratio | -2.77 | -2.99 | -11.57 | -7.91 | -31.33 |
| Debt to Market Cap | 0.22 | 0.27 | 0.01 | 0.02 | 0.05 |
| Interest Debt Per Share | 9.00 | 9.03 | 1.82 | 1.90 | 2.16 |
| Net Debt to EBITDA | -59.66 | 0.60 | 6.94 | 8.37 | 1.41 |
| Profitability Margins | |||||
| Gross Profit Margin | 97.91% | 97.76% | 99.58% | 96.33% | 100.00% |
| EBIT Margin | -0.69% | -16.88% | -22.35% | -29.65% | -477.76% |
| EBITDA Margin | 0.13% | -15.53% | -20.71% | -26.59% | -456.95% |
| Operating Profit Margin | -11.34% | -22.70% | -23.91% | -29.66% | -478.53% |
| Pretax Profit Margin | -4.77% | -17.07% | -24.41% | -23.45% | -493.04% |
| Net Profit Margin | -8.88% | -16.45% | -22.17% | -30.13% | -493.45% |
| Continuous Operations Profit Margin | -8.88% | -16.47% | -22.17% | -30.13% | -493.45% |
| Net Income Per EBT | 185.94% | 96.42% | 90.80% | 128.52% | 100.08% |
| EBT Per EBIT | 42.11% | 75.19% | 102.08% | 79.07% | 103.03% |
| Return on Assets (ROA) | -3.33% | -4.04% | -9.26% | -8.25% | -44.20% |
| Return on Equity (ROE) | -9.32% | -11.31% | -14.99% | -12.83% | -77.76% |
| Return on Capital Employed (ROCE) | -5.53% | -7.06% | -13.02% | -10.04% | -53.77% |
| Return on Invested Capital (ROIC) | -5.51% | -6.80% | -11.79% | -10.00% | -53.49% |
| Return on Tangible Assets | -3.33% | -4.04% | -9.26% | -8.25% | -44.20% |
| Earnings Yield | -2.03% | -2.77% | -1.66% | -2.02% | -16.75% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.41 | 2.98 | 4.06 | 2.53 | 1.09 |
| Payables Turnover | 0.34 | 0.22 | 0.06 | 0.37 | 0.00 |
| Inventory Turnover | 1.24 | 1.02 | 0.23 | 7.65 | 0.00 |
| Fixed Asset Turnover | 7.96 | 5.20 | 5.84 | 3.72 | 0.86 |
| Asset Turnover | 0.37 | 0.25 | 0.42 | 0.27 | 0.09 |
| Working Capital Turnover Ratio | 0.55 | 0.48 | 0.65 | 0.45 | 0.20 |
| Cash Conversion Cycle | -702.53 | -1171.65 | -4590.34 | -804.07 | 335.40 |
| Days of Sales Outstanding | 67.50 | 122.31 | 89.90 | 144.45 | 335.40 |
| Days of Inventory Outstanding | 294.60 | 358.55 | 1584.25 | 47.71 | 0.00 |
| Days of Payables Outstanding | 1064.63 | 1652.50 | 6264.48 | 996.23 | 0.00 |
| Operating Cycle | 362.11 | 480.85 | 1674.15 | 192.16 | 335.40 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.21 | 0.52 | 0.06 | -1.08 | -3.37 |
| Free Cash Flow Per Share | -0.30 | 0.42 | -0.05 | -1.12 | -3.40 |
| Dividend Paid and CapEx Coverage Ratio | -2.47 | 5.04 | 0.54 | -22.34 | -103.25 |
| Capital Expenditure Coverage Ratio | -2.47 | 5.04 | 0.54 | -22.34 | -103.25 |
| Operating Cash Flow Coverage Ratio | -0.02 | 0.06 | 0.03 | -0.60 | -1.66 |
| Operating Cash Flow to Sales Ratio | -0.03 | 0.11 | 0.01 | -0.34 | -3.92 |
| Free Cash Flow Yield | -0.86% | 1.42% | -0.07% | -2.38% | -13.44% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -48.72 | -28.92 | -60.41 | -49.62 | -5.97 |
| Price-to-Sales (P/S) Ratio | 4.37 | 5.95 | 13.39 | 14.95 | 29.46 |
| Price-to-Book (P/B) Ratio | 4.59 | 4.09 | 9.06 | 6.36 | 4.64 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -116.10 | 70.60 | -1344.10 | -41.95 | -7.44 |
| Price-to-Operating Cash Flow Ratio | -163.13 | 56.59 | 1136.09 | -43.83 | -7.51 |
| Price-to-Earnings Growth (PEG) Ratio | 1.62 | -1.98 | -3.19 | 0.71 | -0.17 |
| Enterprise Value Multiple | 3300.92 | -37.70 | -57.73 | -47.86 | -5.04 |
| Enterprise Value | 1.72B | 1.45B | 2.98B | 1.84B | 839.97M |
| EV to EBITDA | 3300.92 | -37.70 | -57.73 | -47.86 | -5.04 |
| EV to Sales | 4.29 | 5.85 | 11.95 | 12.73 | 23.02 |
| EV to Free Cash Flow | -114.04 | 69.50 | -1199.80 | -35.71 | -5.81 |
| EV to Operating Cash Flow | -160.24 | 55.70 | 1014.12 | -37.31 | -5.87 |
| Tangible Book Value Per Share | 7.57 | 7.22 | 7.54 | 7.41 | 5.45 |
| Shareholders’ Equity Per Share | 7.57 | 7.22 | 7.54 | 7.41 | 5.45 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.86 | 0.03 | 0.09 | -0.29 | -0.00 |
| Revenue Per Share | 7.95 | 4.96 | 5.10 | 3.16 | 0.86 |
| Net Income Per Share | -0.71 | -0.82 | -1.13 | -0.95 | -4.24 |
| Tax Burden | 1.86 | 0.96 | 0.91 | 1.29 | 1.00 |
| Interest Burden | 6.96 | 1.01 | 1.09 | 0.79 | 1.03 |
| Research & Development to Revenue | 0.69 | 0.72 | 0.66 | 0.58 | 2.75 |
| SG&A to Revenue | 0.41 | 0.49 | 0.00 | 0.00 | 3.27 |
| Stock-Based Compensation to Revenue | 0.00 | 0.14 | 0.13 | 0.23 | 1.34 |
| Income Quality | 0.30 | -0.51 | -0.07 | 0.94 | 0.79 |
Currency in GBP

